Iit About iGEM

The iGEM competition is an annual, worldwide synthetic biology event aimed at undergraduate university students. It began in January 2003 as an independent study course at MIT (Massachusettes ), USA and currently around 4000 students and 350+ Teams across the world participate to solve local and global problems using the tools of Synthetic Biology or Biology 2.0. Synthetic Biology

Welcome to the world of synthetic biology, or ‘synbio’, where possibilities are limited only by the imagination. Its practitioners don’t view life as a mystery but as a machine – one that can be designed to solve a slew of pressing global health, energy and environmental problems. The Team

We are a team of Undergraduates, Masters and PhDs who share a vision of impacting the globe through Synthetic Biology. We have students aboard from various disciplines, contributing to solve one of the major problems the healthcare industry faces today. iGEM provides us with a really great platform which enables us to execute things beyond capabilities at the global level. The Problem

Antimicrobial Resistance & Superbugs: A rundown of the global public health crisis

Antimicrobial Resistance (AMR) is a condition when microorganisms – bacteria, fungi, viruses, and parasites – evolve resistance to antimicrobial substances, like antibiotics. It is projected to have a devastating effect on the world, creating a medical emergency much larger than the current coronavirus pandemic. is emerging as the epicentre of this phenomenon, where nearly 60,000 newborns every year die of MDR infections with a mortality rate of more than 70%. This can occur naturally through adaption to the environment, which is accelerated due to incessant and uncontrolled use of antibiotics. Our Solution Pyomancer: Engineering novel antibacterial protein complexes for treating drug resistant infections Bacteriophages are viruses that naturally kill bacteria. We aim to combine the properties of phages with natural antibacterial proteins to generate targeted antibacterials. Declared “Priority 1 (Most Critical)” by WHO, A. baumannii is found in many healthcare environments and is also a very effective human colonizer. The combination of its environmental resilience and its wide range of resistance determinants renders it a successful nosocomial pathogen. So we plan to use our engineered novel antibacterial protein to target critical pathogens like A. baumannii. Let’s Work Together

https://igembtiitr.github.io/wiki/

[email protected]

+91 6376 912 644 +91 8875 372 143

The Department of Biotechnology, Indian Institute of Technology, Roorkee Roorkee, , India - 247667